menu
    • menu

    Company profile for Optinose

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Optinose is a specialty pharmaceutical company focused on the development and commercialization of products for patients cared for by, or in consultation with, ear, nose, and throat (ENT) or allergy specialists. We are focused on value creation, starting with our work on a unique and novel drug delivery concept known as Bi-Directional™ Exhalation Delivery Systems. The innovative mechanism of action of the first Optinose t...
    Optinose is a specialty pharmaceutical company focused on the development and commercialization of products for patients cared for by, or in consultation with, ear, nose, and throat (ENT) or allergy specialists. We are focused on value creation, starting with our work on a unique and novel drug delivery concept known as Bi-Directionalâ„¢ Exhalation Delivery Systems. The innovative mechanism of action of the first Optinose technology is designed to enable broad, consistent drug delivery high and deep in the nasal passages, leveraging the mucosal surfaces as a potential target for the treatment of both local and systemic diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OptinoseUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1020 Stony Hill Road, Suite 300 Yardley, Pennsylvania 19067
    Telephone
    Telephone
    267-364-3500
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.optinose.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Optinose Reports Q4 and Full Year 2024 Financial Results
    Optinose Reports Q4 and Full Year 2024 Financial Results

    26 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/26/3049479/0/en/Optinose-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Recent-Operational-Highlights.html

    GLOBENEWSWIRE
    26 Mar 2025
    Share Share
    Paratek buys Optinose, rhinosinusitis spray Xhance for up to $330M
    Paratek buys Optinose, rhinosinusitis spray Xhance for up to $330M

    21 Mar 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/paratek-acquires-optinose-and-rhinosinusitis-spray-xhance-330m

    FIERCE PHARMA
    21 Mar 2025
    Share Share
    Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call
    Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

    19 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/20/3045910/0/en/Optinose-Cancels-Fourth-Quarter-and-Full-Year-2024-Earnings-Call.html

    GLOBENEWSWIRE
    19 Mar 2025
    Share Share
    Optinose Sets Date for Q4 and Full Year 2024 Financial Results
    Optinose Sets Date for Q4 and Full Year 2024 Financial Results

    11 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/11/3041010/0/en/Optinose-Announces-Reporting-Date-for-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html

    GLOBENEWSWIRE
    11 Mar 2025
    Share Share
    Optinose Reports Strong Q4 Revenue For XHANCE Product
    Optinose Reports Strong Q4 Revenue For XHANCE Product

    15 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/15/3009895/0/en/Optinose-Announces-Preliminary-Unaudited-Fourth-Quarter-2024-XHANCE-Net-Revenue-of-22-4-Million.html

    GLOBENEWSWIRE
    15 Jan 2025
    Share Share
    Optinose Announces 1-for-15 Reverse Stock Split
    Optinose Announces 1-for-15 Reverse Stock Split

    26 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/26/3001923/0/en/Optinose-Announces-1-for-15-Reverse-Stock-Split.html

    GLOBENEWSWIRE
    26 Dec 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search